# Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

> **NCT06908772** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 390 (estimated)

## Conditions studied

- Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression

## Interventions

- **DRUG:** Glumetinib Tablets
- **DRUG:** Osimertinib Mesylate Tablets
- **DRUG:** Glumetinib Tablets Placebo

## Key facts

- **NCT ID:** NCT06908772
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2030-01-31
- **Target enrollment:** 390 (ESTIMATED)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06908772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06908772, "Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06908772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*